Christopher S. Shain, PharmD, BCPS, Assistant Vice President, McKesson 340B Solutions
Articles by Christopher S. Shain, PharmD, BCPS, Assistant Vice President, McKesson 340B Solutions
Understanding and Navigating Specialty and Orphan Drug Challenges in the 340B Program
ByLisa Nezneski, PharmD, BCPS, Managing Consultant, McKesson 340B Solutions,Christopher S. Shain, PharmD, BCPS, Assistant Vice President, McKesson 340B Solutions,Andrew L. Wilson, PharmD, FASHP, Vice President, McKesson 340B Solutions Failure to recognize the interests of manufacturers to ensure proper use of 340B pricing may result in 340B hospitals missing the opportunity to secure and retain discounts on key orphan and specialty drugs or may render them unable to access the drugs at all.
